Comparison

FL-411

Item no. CS-0034229-10mg
Manufacturer ChemScene
Amount 10mg
Category
Type Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 2118944-88-8
Available
Alternative Names
BRD4-IN-1
CAS
2118944-88-8
Purity
>98%
Formula
C18H19N3O2S
MWt
341.43
Solubility
DMSO : 5.4 mg/mL (15.82 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)
Clinical Information
No Development Reported
Pathway
Epigenetics
Target
Epigenetic Reader Domain
Biological Activity
FL-411 is a potent and selective BRD4 inhibitor with an IC50 of 0.43+/-0.09 uM for BRD4(1). IC50 & Target: IC50: 0.43+/-0.09 uM (BRD4(1))[1] In Vitro: FL-411 is a selective BRD4 inhibitor. Binding affinities of FL-411 are measured by TR-FRET against the first and second bromodomains of BRD2(1), BRD4(1), and BRD4(2) with IC50s of 24.60+/-0.70 uM, 0.47+/-0.02 uM, 0.93+/-0.05 uM, respectively. FL-411 possesses a good BRD4(1) inhibition activity (IC50=0.43+/-0.09 uM), antiproliferative activity (MCF-7, IC50=1.62+/-0.06 uM; MDA-MB-231, IC50=3.27+/-0.14 uM), and autophagic activity (42.29% in MCF-7 cells), as well as displays a low toxicity against MCF10A cells). FL-411 induces ATG5-dependent autophagy-associated cell death (ACD) by blocking BRD4-AMPK interaction and thus activating AMPK-mTOR-ULK1-modulated autophagic pathway in breast cancer cells[1]. In Vivo: To evaluate the antitumor activity of FL-411 in vivo, two breast tumor xenograft models, namely, MCF-7 and MDA-MB-231 cell lines models, are used. The in vivo study is conducted using three different doses of FL-411: 25 mg/kg, 50 mg/kg, and 100 mg/kg. In all the models, FL-411 shows significant tumor growth inhibition in a dose-dependent manner as determined by 80% and 76% tumor growth inhibition ratio in MCF-7 and MDA-MB-231 cell models, respectively. A remarkable loss of tumor weights is observed in all dose groups (p<0.001). FL-411 displays no obvious effects on the body weight of all the treatment groups. To examine whether FL-411-mediated inhibition of tumor growth in vivo is associated with reduced cell proliferation and the increased autophagy-associated cell death, tumor tissues from control and FL-411-treated mice are processed for the immunohistochemical analysis of Ki-67 and LC3. FL-411 treatment obviously reduces the number of Ki-67 (p<0.001) positive cells as well as increases autophagy levels, which is determined by increased LC3 expression (p<0.001)[1].

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close